Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: J Pediatr. 2016 Nov 29;182:184–189.e1. doi: 10.1016/j.jpeds.2016.11.011

Figure 3.

Figure 3

Phospholamban Ser16 (Panel A) and Thr17 (Panel B) phosphorylation in pediatric non-failing, failing, and failing hearts treated with an LVAD (F-LVAD, L) with representative Western blots normalized to GAPDH. Phospholamban Ser16 phosphorylation is significantly higher in LVAD treated hearts compared with nonfailing and failing. (*) P<0.05. PLN, phospholamban.